Dr. Bio.. Your take is refreshing.
As the CEO said, this is a defining moment for Integenx.
"Not only is the company worth more by virtue of owning a drug that is fully approved by the FDA, but the market should put a lower discount rate on the probability of success for the other 10 drugs in their pipeline, now that they have taken a drug all the way from development through to FDA approval.
The fact that most of their drugs are on the 505b2 pathway to approval is also very significant because that is a far less capital intensive development path than the traditional PhaseI-II-III path; assuming they can sell or license this newly approved drug to another company, I don't believe they will be forced to raise money again. (Note that Intelgenx's cash balance only declined by $100,000 between June 30, 2011 and September 30, 2011; the financing they did with Rodman Renshaw closed in June, so had nothing to do with the fact cash only went down by $100,000.) "
FCSC? I think not.
